Cancer Care Commission met with Dr Yu, President of PUIH and the Director of Oncology to discuss collaboration and CCC support for Translational Research.
Calum Kerr, along with Dr Fred Sun were welcomed to CR Huaibei Hospital to discuss the support and development required to meet the needs of the hospital, as well as deliver some key lectures.
Calum Kerr and Dr Nidhin Raj performed a clinical and operational assessment of Wuhan No.2 hospital at the end of May, in preparedness for their assessment in Autumn of 2019. Dr Raj commented that, “, It was a pleasure visiting the Wuhan No 2 Hospital. I see great potential…”
The assessors observed an MDT (Multi-Disciplinary Team) in the Oncology Department.
Calum Kerr also took the opportunity to present the Cancer Care Commission short Oncology course certificate to the team who had visited NHS Oxford the week before.
As part of our CCC Education and Development Programme, colleagues from WUHAN came to NHS Oxford Cancer Centre on 5th May, to experience Cancer Care in the U.K. The clinical staff took many ideas and practices back to Wuhan No. 2 Hospital. The staff are pictured with Mr Calum Kerr, Executive Director and Prof David Kerr , President of CCC.
Chairman Fu Yuning took time out of his busy international schedule to witness the signing ceremony between Cancer Care Commission, CRMedical Oncology Centre and Wuhan no.2 hospital. Calum Kerr stated “CCC has been commissioned to introduce a Quality Improvement Accreditation Programme, in association with CRMOC into Wuhan No.2 Hospital in the Hubei Province”, he added “This is the expansion of the CCC Accreditation process in China, it is an exciting time for us and we will be keeping the impetus moving forward”.
Calum Kerr of CCC was honoured to visit the pleasant, calming surroundings of the China Resources University Campus in Baiyangdian District. Calum said “The facilities and atmosphere at the Campus are ideally suited to facilitate a first class learning environment”
Cancer Care Commission (CCC) fully supports the Chinese Government’s and National Cancer Centre’s (NCC) strategy to make cancer drugs more affordable to the general public. CCC participated in the UK Trade Mission to China in association with NCC, where this aspiration was highlighted. CCC President, Professor David Kerr stated “This is a major step towards addressing the burden of cancer in China. This decision is to be applauded.”
China approves 17 anti-cancer drugs for medical insurance coverage
SHANGHAI (Reuters) – China has approved 17 anti-cancer drugs for inclusion in its national health insurance system, the government said on Wednesday, part of its efforts to make cancer treatment more affordable as the number of cases increases.
China’s State Medical Insurance Administration has been in negotiations with domestic and overseas pharmaceutical companies to lower prices and put more cancer drugs on the list of medicines eligible for reimbursement.
China’s cancer rates have been soaring, driven by growing numbers of over-60s, heavy smoking among men and exposure to pollution. The National Cancer Center said last year there were 4.29 million new cases every year and 2.81 million deaths.
China has vowed to improve the five-year cancer survival rate by 15 percentage points by 2030. The rate stood at 30 percent in 2015.
Here are a few photos of speakers and delegates at IFQCC18, Keble College, Oxford:
Zahira Fahed and Maha Manachi were welcome guests at Cancer Care Commission, where they presented a Poster
MSP Miles Briggs, Shadow Cabinet Secretary for Health and Sport and co-convener of Parliamentary Cross Party group on cancer gave a keynote speech at the IFQCC18, Keble College, Oxford. Miles gave an overview of cancer management in Scotland and highlighted the challenges ahead. Miles participated in a panel discussion on the global cancer burden and put forward his Politician’s opinion on ….’Can policy drive real improvements’. The session was well received by the international audience.